Where IGM Biosciences Stands With Analysts
Portfolio Pulse from Benzinga Insights
IGM Biosciences (NASDAQ:IGMS) has been rated by 5 analysts over the past 3 months, with 3 bullish and 2 indifferent ratings. The average 12-month price target is $15.4, representing a 10.72% decrease from the previous target of $17.25. The high target is $25.00 and the low target is $8.00. Analysts' ratings are based on research and provide guidance to investors, though they reflect opinions and may vary each quarter.
November 15, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
IGM Biosciences has received mixed analyst ratings, with an average price target suggesting a potential downside. This could influence investor sentiment and impact the stock price.
Analyst ratings can significantly affect investor sentiment, especially when the average price target is reduced. The reduction in the average price target for IGMS suggests that analysts see less upside potential, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100